Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
IMUC > SEC Filings for IMUC > Form 8-K on 18-Apr-2013All Recent SEC Filings

Show all filings for IMMUNOCELLULAR THERAPEUTICS, LTD. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for IMMUNOCELLULAR THERAPEUTICS, LTD.


18-Apr-2013

Entry into a Material Definitive Agreement, Financial Statement


Item 1.01. Entry into a Material Definitive Agreement.

On April 18, 2013, ImmunoCellular Therapeutics Ltd. (the "Company," "we," "us," or "our") entered into a Controlled Equity OfferingSM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co., as agent ("Cantor"), pursuant to which we may offer and sell, from time to time through Cantor, shares of our common stock par value $0.0001 per share (the "Common Stock") having an aggregate offering price of up to $25.0 million (the "Shares").

Under the Sales Agreement, Cantor may sell Shares by any method permitted by law and deemed to be an "at-the-market" offering as defined in Rule 415 promulgated under the Securities Act, as amended (the "Securities Act"), including sales made directly on the NYSE MKT, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the Sales Agreement, Cantor may sell the Shares by any other method permitted by law, including in privately negotiated transactions. We may instruct Cantor not to sell Shares if the sales cannot be effected at or above the price designated by us from time to time.

We are not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or
(b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein.

We will pay Cantor a commission rate of 3.0% of the aggregate gross proceeds from each sale of Shares and have agreed to provide Cantor with customary indemnification and contribution rights. We will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement.

The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The opinion of our counsel regarding the validity of the Shares that will be issued pursuant to the Sales Agreement is also filed herewith as Exhibit 5.1.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the common stock discussed herein, nor shall there be any offer, solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.




Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit                                   Description

 5.1         Opinion of Cooley LLP.

10.1         Controlled Equity OfferingSM Sales Agreement, dated April 18, 2013, by
             and between ImmunoCellular Therapeutics, Ltd. and Cantor Fitzgerald &
             Co.

23.1         Consent of Cooley LLP (included in Exhibit 5.1).


  Add IMUC to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for IMUC - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.